Firstly, given that EZH2 inhibitors have been developed for cancer therapy,53 our in vitro data suggest that combining external beam RT and EZH2 inhibitors to treat PCa patients may not result in clinical benefit in terms of radiosensitization per se. Here, EZH2 is linked to cancer.